

The effects of short-term norepinephrine uptitration on hemodynamics in cardiogenic shock.

Richard Rokyta Jr, Jitka Tesařová, Vratislav Pechman, Petr Gajdoš, Aleš Kroužecký.

Intensive Cardiac Care Unit, Departement of Medicine I, School of Medicine Plzen, Charles University Prague, Czech Republic

**Correspondance:** Assoc. prof. Richard Rokyta Jr, M.D., Ph.D. Intensive Cardiac Care Unit, Departement of Medicine I, School of Medicine, Charles University, Alej svobody 80, 323 00 Plzen, Czech Republic.  
Phone +420 377103160, fax +420 377103163, e-mail [rokyta@fnplzen.cz](mailto:rokyta@fnplzen.cz)

**Short title:** Norepinephrine titration in cardiogenic shock.

## **Summary**

A higher mean arterial blood pressure achieved by norepinephrine uptitration may improve organ blood flow in critically ill, whereas norepinephrine-induced afterload rise might worsen myocardial function. Our aim was to assess the effects of norepinephrine dose titration on global hemodynamics in cardiogenic shock. We prospectively evaluated 12 mechanically ventilated euvolemic patients (age  $67\pm 12$  years) in cardiogenic shock (10 pts acute myocardial infarction, 1 pt dilated cardiomyopathy, 1 pt decompensated aortic stenosis). Hemodynamic monitoring included arterial and Swan Ganz catheters. The first data were obtained at mean arterial pressure 65 mmHg, then the norepinephrine dose was increased over 40 minutes to achieve mean arterial pressure 85 mmHg. Finally, the norepinephrine-dose was tapered over 40 minutes to achieve mean arterial pressure 65 mmHg. Norepinephrine up-titration increased mean arterial pressure to the predefined values in all patients with concomitant mild increase in filling pressures and heart rate. Systemic vascular resistance increased whereas cardiac output remained unchanged. During norepinephrine downtitration, all hemodynamic parameters returned to baseline values. We observed no changes in lactatemia and mixed venous oxygen saturation. Our data suggest that

short-term norepinephrine dose up-titration in cardiogenic shock patients treated or pretreated by inotropes was tolerated well by the diseased heart.

**Key words:** norepinephrine; cardiac function; shock; hemodynamics; pressure

## **Introduction**

Neurohumoral activation, including increased endogenous catecholamine levels (norepinephrine and epinephrine), is a hallmark pathophysiological condition in chronic heart failure patients and in the long-term it has several harmful effects (Francis 1985). Conversely, exogenous catecholamines are widely administered to well volume-resuscitated critically ill patients in various clinical scenarios. The primary aim of this treatment is the preservation of adequate organ blood flow keeping mean arterial pressure above the autoregulatory organ perfusion pressure threshold (Albanese *at al.* 2004, Matějovič 2005, Ďurišová *at al.* 2008). In physiological conditions, the organ blood flow is usually preserved over a wide range of mean arterial pressure (MAP). When MAP is less than 65 mmHg, the organ blood flow may be compromised. In certain subgroups of intensive care unit patients (e.g. patients with preexisting arterial hypertension, after cardiopulmonary resuscitation,

sepsis etc.), the optimal target value of MAP may be even higher than usually accepted values of 65-70 mm Hg (i. e. above 80-90 mmHg) (Matějovič 2005, Marik 2004, Tamborini *at al.* 2001). The influence of norepinephrine dose uptitration (resulting in a higher MAP usually within physiological range) on global and regional hemodynamics in sepsis (high cardiac output at baseline) has been assessed in several experimental and clinical studies showing no detrimental effects on global hemodynamics or cardiac function (Bourgoin *at al.* 2005, LeDoux *at al.* 2000, Di Giantomasso *at al.* 2003, Kroužecký *at al.* 2006). However, such an approach might worsen myocardial performance in critically ill patients with a failing or injured heart due to norepinephrine induced rise in afterload (Heusch 1990, Zeeuw *at al.* 2001). To our knowledge, hemodynamic studies on MAP changes within physiological range induced by norepinephrine titration in patients with acute forms of ischemic heart disease or low cardiac output states are lacking. Therefore, we have conducted a prospective clinical trial to assess the short term effects of various norepinephrine doses (leading to clinically significant MAP changes) on global hemodynamics in cardiogenic shock patients.

## **Methods**

The study followed the principles established in the Declaration of Helsinki. The protocol was accepted by the local ethics committee and informed consent was obtained from the patients or next of kin. This study was performed in intensive cardiac care unit in a tertiary medical centre.

### ***Patients***

We evaluated 12 patients (age  $67 \pm 12$  years, male/female 8/4, patients' characteristics - Table 1) fulfilling the following inclusion criteria:

- 1) Pulmonary arterial occlusion pressure (PAOP)  $\geq 15$  mmHg
- 2) The need for catecholamines to maintain MAP  $\geq 65$  mmHg
- 3) Cardiac index  $\leq 2,5$  l/min/m<sup>2</sup>
- 4) Age 18-80 years

The exclusion criteria were major hemodynamic and/or electrical instability. All patients were mechanically ventilated (no ventilatory changes during the study) and sedated with midazolam and fentanyl. Three patients had atrial fibrillation and 9 patients had sinus rhythm throughout the study. All but one patient (i.e. 9 patients) with ST elevation myocardial infarction (STEMI) were treated with primary percutaneous coronary intervention (PCI) with stent implantation. Three patients were

on intraaortic balloon counterpulsation. Six patients were given dobutamine in constant dosages (2-10 ug/kg/min) during the study and 8 patients received levosimendan in previous days in the intensive care unit.

### ***Methods***

Hemodynamic monitoring included arterial and pulmonary arterial thermodilution catheters (Swan-Ganz hands-off infusion port catheter 7, 5 Fr, Arrow®, Reading, USA). Both pulmonary arterial occlusion pressure (PAOP) and cardiac output (CO) were measured at end-expiration. Cardiac output was measured in triplicate at each time point (10 ml of room temperature saline, CO-set + closed injectate delivery system, Edwards Lifesciences, Unterschleissheim, Germany) and the mean of the three measurements was taken for calculations. Systemic and pulmonary vascular resistances (SVR and PVR) as well as left ventricular stroke work index (LVSWI) were calculated according to standard formulae. Blood gases were measured using a blood gas analyzer (ABL 520®, Radiometer, Copenhagen, Denmark), and haemoglobin oxygen saturation was determined by a co-oximeter (OSM-3, Radiometer ).

### ***Protocol (Fig. 1)***

Before the study, adequate fluid resuscitation was ensured on the individual basis by monitoring filling pressures (central venous pressure and pulmonary arterial occlusion pressure) and cardiac output with eventual subsequent fluid challenge. Afterwards, norepinephrine (NE) dose was titrated over approximately 40 minutes to achieve mean arterial pressure (MAP) 65 mm Hg (at least 30 minutes in a steady state). At MAP of 65 mmHg, the first data set was obtained, then NE dose was increased over 40 minutes to achieve MAP of 85 mmHg (2<sup>nd</sup> data set). Finally, the NE dose was tapered down over 40 minutes to achieve again MAP of 65 mmHg (3<sup>rd</sup> data set). During the study fluid infusion rates were kept constant, no red blood cells were given and no nursing procedures were performed.

### ***Statistics***

All values shown are medians; 25<sup>th</sup> and 75<sup>th</sup> percentiles if not otherwise stated. The differences between the periods were analysed by the Friedman Repeated Measures Rank Sign Analysis of Variance and a subsequent Dunn's test for multiple comparisons when appropriate. The patients served as their own controls. Statistical significance was considered at  $p < 0, 05$ .

## **Results (Table 2)**

The study was performed on the 1<sup>st</sup> - 5<sup>th</sup> day of the intensive care unit stay. All patients required norepinephrine before the study to achieve mean arterial pressure  $\geq 65$  mmHg. No clinical adverse effects were registered during NE titration. NE up-titration (to approximately double dose vs. baseline in the majority of patients) increased MAP to the predefined values in all patients (Fig. 2). We observed a mild increase in cardiac filling pressures (Table 2, Fig. 3). Systemic and pulmonary vascular resistances increased at a higher MAP. This response with a subsequent return to baseline values at NE down titration was uniform in all patients. The observed changes in heart rate and stroke volume did not reach statistical significance. Cardiac output (CO) increased or remained unchanged in 10 patients during NE up-titration (Fig. 4). In 2 patients (No.5 and No.10), we observed CO decrease at a higher MAP due to the worsening of mitral regurgitation (W wave increase). Neither arterial lactate values, nor mixed venous oxygen saturation changed during the study.



## **Discussion**

The main finding of our study was that norepinephrine (NE) induced rise of systemic vascular resistance and mean arterial pressure (MAP within a normal range of 65-85 mmHg) did not compromise cardiac output in the majority of our patients (Fincke *at al.* 2004).

In our study, all patients were euvolemic (individual preload optimisation before the study). During norepinephrine uptitration, we observed a mild increase in both central venous and pulmonary arterial occlusion pressures (PAOP) which may be explained by the rise in systemic venous tone and pulmonary vascular tone and partly by shorter diastole due to a mild heart rate increase. Cardiac output remained unchanged despite the rise of both systemic and pulmonary vascular resistances presumably due the combined effect of norepinephrine both on alfa and beta adrenergic receptors. Nevertheless, the hemodynamic response to increased MAP in our study might have been influenced by the treatment with positive inotropic drugs (dobutamine in moderate stable doses and/or levosimendan in previous days) and thus we cannot exclude that cardiac output changes could be different in patients without previous or concurrent inotropic support.

During NE uptitration, clinician may expect hemodynamic deterioration in patients with severe mitral regurgitation (MR), where

norepinephrine induced rise in systemic vascular resistance may lead to cardiac output decrease (afterload mismatch). We observed a mild cardiac output decrease in 2 patients during NE uptitration due to the worsening of mitral regurgitation (W wave increase/appearance). One patient had moderate to severe MR (3/4) already at baseline, whereas the second patient had only mild MR (1/4) at baseline. Therefore, before eventual norepinephrine uptitration, caution is needed when MR is detected on echocardiography and/or W wave is present during pulmonary arterial occlusion pressure measurement.

It is assumed that certain subgroups of critically ill patients might benefit from higher organ perfusion pressures, at least during limited time periods (Albanese *at al.* 2004, Marik 2004). The optimal MAP value may differ in (1) different patient populations (e.g. preexisting arterial hypertension, when autoregulatory renal perfusion pressure is shifted to higher values), (2) various stages of critical illness, e.g. the early phase in patients after cardiopulmonary resuscitation, when higher cerebral perfusion pressure is required or during sepsis when vasoplegia and altered vascular reactivity may result in a shift of the autoregulatory threshold to higher values), (3) various organs also depending on different degree of stenotic atherosclerotic process (Marik 2004, Tamborini *at al.* 2001, Koužecký *at al.* 2006, Martin *at al.* 1999).

In a healthy heart, coronary blood flow remains stable within a wide range of coronary perfusion pressures (50-70 to 110-130 mm Hg) (Bourdarias 1995, Jones *at al.* 1995, Bellomo 2003). Norepinephrine leads to vasoconstriction of coronary arteries and coronary perfusion pressure (CPP) elevation (Heusch 1990). In experimental studies in sheep, short term NE up titration significantly increased coronary blood flow (Di Giantomasso *at al.* 2003, Bellomo 2003). In our study, we did not measure coronary blood flow directly. NE induced a significant MAP rise and a mild increase in PAOP, thus presumably also a mild increase of left ventricular enddiastolic pressure (LVEDP). Hence, we can assume that CPP (MAP-LVEDP) rised since the shortening of diastole (only mild heart rate increase) was not clinically significant (Vis *at al.* 1997). Importantly, the majority of our patients had successful percutaneous coronary revascularisation with stent implantation before the study. We can only speculate that the effect of NE may be different in patients with persistent significant coronary artery stenosis, when the autoregulatory threshold of CPP may be shifted to higher values (Marik 2004).

### *Study limitations*

Our study has certain limitations. First, the time periods for norepinephrine up and downtitration were short and the NE dose increase

was relatively mild. Exposure to higher NE doses with more pronounced LV and RV afterload and/or heart rate increase might worsen cardiac performance due to the rise in myocardial oxygen demand or due to catecholamine induced myocardial stunning (Zeeuw *at al.* 2001, Bolli and Marban 1999). Moreover, Rump et al., in isolated rabbit hearts, demonstrated direct cardiotoxic effects of NE mediated by superoxide anion radicals depending on the dose of exogenous NE (Rump *at al.* 2002). In experimental studies it has also been shown, that long term NE administration may induce cardiac fibrosis and/or left ventricular hypertrophy contributing to functional deterioration and heart failure exacerbation (Briest *at al.* 2001, Meier *at al.* 2007).

Second, our analysis was focused only on global hemodynamic and metabolism and not on regional hemodynamics. In previous studies, it has not been convincingly shown that higher MAP values improves regional blood flow (Zhang *at al.* 1997). In our recent experimental study in pigs with hyperdynamic septic shock, we have shown that neither intestinal macro nor microcirculation was compromised by norepinephrine uptitration (Kroužecký *at al.* 2006). In the present human study, we found that the indices of global oxygen kinetics and metabolism were unaltered, but we cannot make any conclusion concerning regional blood flows and

metabolism. Due to the short-term protocol of this study, we did not measure potential urine output changes.

## **Conclusion**

We conclude that short-term norepinephrine dose up-titration leading to mild mean arterial pressure rise in euvoletic cardiogenic shock patients treated or pretreated by inotropes was tolerated well by the diseased heart. Our observation may be in favor of possible safe norepinephrine use in order to achieve a higher organ blood flow also in critically ill patients with compromised cardiac function under careful hemodynamic monitoring. Caution is needed in patients with mitral regurgitation. However, the impact of long term norepinephrine infusion on cardiac function in this patient population requires further studies.

## **Acknowledgement**

Financial support by the cardiovascular research project of the Charles University Prague, nr. MSM0021620817 „Invasive approach to myocardial salvage and regeneration“

## References

- ALBANESE J, LEONE M, GARNIER F, BOURGOIN A, ANTONINI F, MARTIN C: Renal effects of norepinephrine in septic and nonseptic patients. *Chest* **126**: 534-539, 2004.
- BELLOMO R: Noradrenaline: friend or foe? *Heart Lung Circ* **12**: S42-48, 2003.
- BOLLI R, MARBAN E: Molecular and cellular mechanisms of myocardial stunning. *Physiol Rev* **79**: 609-634, 1999.
- BOURDARIAS JP: Coronary reserve: concept and physiological variations. *Eur Heart J* **16**: 2-6, 1996.
- BOURGOIN A, LEONE M, DELMAS A, GARNIER F, ALBANESE J, MARTIN C: Increasing mean arterial pressure in patients with septic shock: Effects on oxygen variables and renal function. *Crit Care Med* **33**: 780-786, 2005.
- BRIEST W, HÖLZL A, RASSLER B, DETEN A, LEICHT M: Cardiac remodelling after long term norepinephrine treatment in rats. *Cardiovasc Res* **52**: 265-273, 2001.
- Di GIANTOMASSO, MAY CN, BELLOMO R: Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis. *Intensive Care Med* **29**: 1774-1781, 2003.
- ŘURIŠOVÁ M, DEDÍK L, KRISTOVA V, VOJTKO R: Mathematical

model indicates nonlinearity of noradrenaline effect on rat renal artery.

*Physiol. Res.* **57**: 785-788, 2008.

FINCKE R, HOCHMAN JS, LOWE AM, MENON V, SLATER

JN, WEBB JG, et al: Cardiac power is the strongest hemodynamic

correlate of mortality in cardiogenic shock: a report from the

SHOCK trial registry. *J Am Coll Cardiol* **44**: 340-348, 2004.

FRANCIS GS: Neurohumoral mechanisms involved in congestive heart

failure. *Am J Cardiol* **55**: 15A-21A, 1985.

HEUSCH G. Alpha-adrenergic mechanisms in myocardial ischemia.

*Circulation* **81**: 1-13, 1990.

JONES CHJH, KUO L, DAVIS MJ, CHILAN WM: Regulation of

coronary blood flow: coordination of heterogeneous control

mechanisms in vascular microdomains. *Cardiovascular Research*

**29**: 585-596, 1995.

KROUŽECKÝ A, MATĚJOVIČ M, RADĚJ J, ROKYTA R Jr, NOVÁK

I: Perfusion pressure manipulation in porcine sepsis: effects on

intestinal hemodynamics. *Physiol Res* **55**: 527-533, 2006.

LeDOUX D, ASTIZ ME, CARPATI CM, RACKOW EC. Effects of

perfusion pressure on tissue perfusion in septic shock. *Crit Care Med*

**28**: 2729-2732, 2000.

MARIK P: Renal dose norepinephrine. *Chest* **126**: 335-337, 2004.

MARTIN C, VIVIAND X, AMAUD S, VIALET R, ROUGNON T:

Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. *Crit Care Med* **27**: 1708-1713, 1999.

MATĚJOVIČ M: Noradrenaline and the kidney: foe, friend, or both?

*Intensive Care Med* **31**: 1476-1478, 2005.

MEIER H, BULLINGER J, DETEN A, MARX G, RABALD S,

ZIMMER HG: Tissue inhibitor of matrix metalloproteinase-1 in norepinephrine- induced remodelling of the mouse heart. *Cell Physiol Bioch* **20**: 825-836, 2007.

RUMP AFE, SCHIERHOLZ J, KLAUS W: Studies on the cardiotoxicity

of noaradrenaline in isolated rabbit hearts. *Arzneim-Forsch/Drug Res* **7**: 543-551, 2002.

TAMBORINI G, MALTAGLIATI A, TRUPIANO L, BERNA G,

SISILLO E, SALVI L, et al: Lowering of blood pressure and coronary blood flow in isolated systolic hypertension. *Coron Artery Dis* **12**: 259-265, 2001.

VIS MA, SIPKEMA P, WESTERHOF N: Modeling pressure-flow

relations in cardiac muscle in diastole and systole. *Am J Physiol* **272**: H 1516-1526, 1997.

ZEEUW S, LAMERIS TW, DUNCKER DJ, HASAN D, BOOMSMA F,



VAN DEN MEIRACKER AH, et al: Cardioprotection in pigs by exogenous norepinephrine but not by cerebral ischemia–induced release of endogenous norepinephrine. *Stroke* **32**: 767-774, 2001.

ZHANG H, SMAIL N, CABRAL A, ROGIERS P, VINCENT JL: Effect of norepinephrine on regional blood flow and oxygen extraction capabilities during endotoxic shock. *Am J Respir Crit Care Med* **155**: 1965-1971, 1997.

**Table 1. Patients' characteristics.**

Pt.	Age	Diagnosis	LVEF/ RVEF (%)	MR	APII	SOFA	ICCU survival
1	79	STEMI	35/55	2/4	14	7	0
2	78	STEMI	30/30	¼	20	12	0
3	75	STEMI	25/60	2/4	14	4	0
4	73	Non-STEMI	30/50	2/4	16	8	0
5	61	DCMP	25/35	¾	13	12	0
6	59	STEMI	25/55	2/4	9	6	1
7	70	Aortic stenosis	20/45	¼	24	10	1
8	65	STEMI	40/55	2/4	22	6	1
9	32	STEMI	20/45	0	20	9	1
10	70	STEMI	30/50	¼	23	7	1
11	74	Non-STEMI	45/60	¼	20	9	1
12	68	STEMI	30/45	¼	25	10	0

**Legend:** LVEF/RVEF- left/right ventricular ejection fraction, MR-degree of mitral

regurgitation, ICCU survival: 0- no, 1- yes, STEMI-ST elevation myocardial infarction,

DCMP-dilated cardiomyopathy

**Table 2. Results**

	MAP 65 (1)	MAP 85	MAP 65 (2)	P
NE-dose (ug/kg/min)	0,13 (0,10;0,20)	0,25 (0,21;0,34) *	0,14 (0,12;0,21) **	<0,001
Heart rate (b.p.m.)	83 (80;102)	90 (81;101)	85 (80;100)	0,49
MAP (mmHg)	67 (65;69)	84 (83;85)*	67 (66;69)**	<0,001
CVP (mmHg)	12 (11;14)	14 (12;15)	12 (10;14)**	<0,001
PAOP (mmHg)	19 (18;20)	23 (21;28)*	19 (17;19)**	<0,001
MPAP (mmHg)	28 (25;30)	33 (29;40)*	28 (25;32)**	<0,001
SVR (dyn*s/cm <sup>5</sup> *m <sup>-2</sup> )	2441 (2039; 2764)	2893 (2332;3869)*	2423 (2008;2725)**	<0,001
PVR (dyn*s/cm <sup>5</sup> *m <sup>-2</sup> )	340 (244;463)	554 (307;748) *	396 (233;513) **	<0,001
Stroke volume (ml/m <sup>2</sup> )	22 (18;25)	21 (18;24)	22 (19;25)	0,98
Cardiac index (l/min/m <sup>2</sup> )	1,9 (1,6;2,3)	1,9 (1,6;2,4)	1,9 (1,6;2,4)	0,90
LVSWI (gm/m <sup>2</sup> /HR)	15 (11;17)	17 (14;22) *	14 (12;18)	<0,05
Lactate (mmol/l)	1,54 (1,43;1,92)	1,50 (1,46;1,85)	1,40 (1,31;1,85)	0,33
SvO <sub>2</sub> (%)	64 (62;69)	64 (62;67)	65 (62;69)	0,79

**Legend:** MAP-mean arterial pressure, NE-norepinephrine, CVP-central venous pressure, PAOP-pulmonary arterial occlusion pressure, MPAP-mean pulmonary arterial pressure, SVR-systemic vascular resistance, PVR – pulmonary vascular resistance, LVSWI-left ventricular stroke work index, SvO<sub>2</sub> – mixed venous hemoglobin oxygen saturation

\*vs. MAP 65 (1) , \*\*vs. MAP 85, NS = nonsignificant

**Figure legends:**

**Figure 1. Study flow chart**

MAP-mean arterial pressure

**Figure 2. Time course of mean arterial pressure**

MAP-mean arterial pressure: individual changes

**Figure 3. Time course of pulmonary arterial occlusion pressure**

PAOP-pulmonary arterial occlusion pressure, MAP-mean arterial pressure

**Figure 4. Time course of cardiac index**

CI-cardiac index, MAP-mean arterial pressure

Fig. 1




Fig. 2




Fig. 3




Fig. 4

